Robin E. Haimbach

p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension

Haisong Ju, David J. Behm, Sandyha Nerurkar et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 64 citations

SB 234551 selective ETA receptor antagonism: Perfusion/Diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection

Jeffrey J. Legos, Stephen C. Lenhard, Robin E. Haimbach et al. · Experimental Neurology · 2008 · 47 citations

Thrombosis, Ischemic Stroke, Medicine +15

An integrin antagonist (<scp>MK</scp>‐0429) decreases proteinuria and renal fibrosis in the <scp>ZSF</scp>1 rat diabetic nephropathy model

Xiaoyan Zhou, Zhang Ji, Robin E. Haimbach et al. · Pharmacology Research & Perspectives · 2017 · 46 citations · Full text

Normalization of Skeletal Muscle Glycogen Synthesis and Glycolysis in Rosiglitazone-Treated Zucker Fatty Rats

Beat M. Jucker, Thomas Schaeffer, Robin E. Haimbach et al. · Diabetes · 2002 · 27 citations · Full text

P Nmr, Metabolic Remodeling, Insulin Signaling +18

Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: An in vivo nuclear magnetic resonance study

Beat M. Jucker, Thomas Schaeffer, Robin E. Haimbach et al. · Metabolism · 2003 · 25 citations

Short-term Rosiglitazone Treatment, Physiology, Lipid Science +3